Search tool

Displaying 931 - 940 of 994

Drugnet Europe 20

Drugnet Europe, the EMCDDA's quarterly newsletter, provides regular information on the Agency's activities to a broad readership. The newsletter aims to offer a complete overview of the work of the Agency and...

Drugnet Europe 19

Drugnet Europe, the EMCDDA's quarterly newsletter, provides regular information on the Agency's activities to a broad readership. The newsletter aims to offer a complete overview of the work of the Agency and...

publication thumbnail

Review and synthesis of scientific literature on drug-related non-fatal emergencies

The aim of this report was to provide a detailed review of epidemiological studies on drug-related emergencies implemented recently (10 years) in the European Union, and to synthesise information generated by all...

Guidelines for the risk assessment of new synthetic drugs

This publication was drawn up by the steering group created by the EMCDDA's Scientific Committee in November 1998 to establish guidelines to assess the risks of all new synthetic drugs identified under...

Drugnet Europe 18

Drugnet Europe, the EMCDDA's quarterly newsletter, provides regular information on the Agency's activities to a broad readership. The newsletter aims to offer a complete overview of the work of the Agency and...

Implementation, follow-up and analysis of cohort studies on mortality among drug users (report 1)

This is the final report from the first phase of a project set up to promote and co-ordinate the setting up of cohorts of drug users recruited through treatment centres, in order...

Scientific review of the literature on estimating the prevalence of drug misuse on the local level

Prevalence of problem drug use (PDU) is one of five key indicators used by the EMCDDA to provide more comparable, scientifically based estimates of the prevalence of more severe patterns of drug...

Outreach work among drug users in Europe: concepts, practice and terminology

Outreach work among drug users in Europe is the culmination of a multi-country study commissioned by the EMCDDA in 1998 to assess the concepts, practice and terminology relating to outreach work among...

Report on the risk assessment of MBDB in the framework of the joint action on new synthetic drugs

On 27 February 1998, the drug MBDB (N-methyl-1-(1,3-benzodioxol- 5-yl)-2-butanamine) became the first new synthetic drug to be submitted for risk assessment under the terms of the Joint Action concerning the information exchange...

Drugnet Europe 17

Drugnet Europe, the EMCDDA's quarterly newsletter, provides regular information on the Agency's activities to a broad readership. The newsletter aims to offer a complete overview of the work of the Agency and...